Abraxis Biosciences LLC withdraws complaint against SPARC’s Taclantis injection

10 Dec 2019 Evaluate

Sun Pharma Advanced Research Company’s (SPARC) patent infringement complaint regarding its New Drug Application for Taclantis injection PICS (Paclitaxel Injection Concentrate for Suspension) has been withdrawn by Abraxis Bioscience LLC. The company will also inform the USFDA of the dismissal of the complaint to vacate the 30-month stay.

Earlier, Abraxis Biosciences LLC has filed a complaint against the company in the US District Court for the district of New Jersey. It alleged that the SPARC’s filing of New Drug Application (NDA) for Taclantis injection (Paclitaxel Injection Concentrate for Suspension) is an act of infringement of the Orange Book listed patents for Abraxane.

SPARC is an international pharmaceutical company engaged in research and development of drugs and delivery systems.

Sun Pharma Adv. Res Share Price

204.40 14.00 (7.35%)
22-Nov-2024 16:59 View Price Chart
Peers
Company Name CMP
Syngene Internation. 869.40
Sagility India 28.03
AGS Transact Tech 79.99
Just Dial 1073.50
Krystal Integrated 643.20
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.